UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival by months. However, resistance often occurs, largely limits its efficacy. Sorafenib was found to target the elect...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Signal Transduct Target Ther
Hlavní autoři: Xu, Junjie, Ji, Lin, Ruan, Yeling, Wan, Zhe, Lin, Zhongjie, Xia, Shunjie, Tao, Liye, Zheng, Junhao, Cai, Liuxin, Wang, Yifan, Liang, Xiao, Cai, Xiujun
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8129126/
https://ncbi.nlm.nih.gov/pubmed/34001851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-021-00594-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky